Catherine E Munro1, Nancy J Donovan2, Rebecca E Amariglio3, Kate V Papp3, Gad A Marshall4, Dorene M Rentz3, Alvaro Pascual-Leone5, Reisa A Sperling6, Joseph J Locascio7, Patrizia Vannini8. 1. Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Boston, MA. 2. Harvard Medical School, Boston, MA; Center for Alzheimer Research and Treatment, Department of Neurology Brigham and Women's Hospital, Boston, MA; Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. 3. Harvard Medical School, Boston, MA; Center for Alzheimer Research and Treatment, Department of Neurology Brigham and Women's Hospital, Boston, MA. 4. Harvard Medical School, Boston, MA; Center for Alzheimer Research and Treatment, Department of Neurology Brigham and Women's Hospital, Boston, MA; Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA. 5. Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. 6. Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA; Center for Alzheimer Research and Treatment, Department of Neurology Brigham and Women's Hospital, Boston, MA; Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA. 7. Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA. 8. Harvard Medical School, Boston, MA; Center for Alzheimer Research and Treatment, Department of Neurology Brigham and Women's Hospital, Boston, MA; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA. Electronic address: patrizia@bwh.harvard.edu.
Abstract
OBJECTIVE: To investigate the relationship of awareness of and concern about memory performance to progression from mild cognitive impairment (MCI) to Alzheimer disease (AD) dementia. METHODS: Participants (n = 33) had a diagnosis of MCI at baseline and a diagnosis of MCI or AD dementia at follow-up. Participants were categorized as "Stable-MCI" if they retained an MCI diagnosis at follow-up (mean follow-up = 18.0 months) or "Progressor-MCI" if they were diagnosed with AD dementia at follow-up (mean follow-up = 21.6 months). Awareness was measured using the residual from regressing a participant's objective memory score onto their subjective complaint score (i.e., residual<0 indicates overestimation of performance). Concern was assessed using a questionnaire examining the degree of concern when forgetting. Logistic regression was used to determine whether the presence of these syndromes could predict future diagnosis of AD dementia, and repeated measures analysis of covariance tests were used to examine longitudinal patterns of these syndromes. RESULTS: Baseline anosognosia was apparent in the Progressor-MCI group, whereas participants in the Stable-MCI group demonstrated relative awareness of their memory performance. Baseline awareness scores successfully predicted whether an individual would progress to AD-dementia. Neither group showed change in awareness of performance over time. Neither group showed differences in concern about memory performance at baseline or change in concern about performance over time. CONCLUSION: These data suggest that anosognosia may appear prior to the onset of AD dementia, while anosodiaphoria likely does not appear until later in the AD continuum. Additionally, neither group showed significant changes in awareness or concern over time, suggesting that change in these variables may happen over longer periods.
OBJECTIVE: To investigate the relationship of awareness of and concern about memory performance to progression from mild cognitive impairment (MCI) to Alzheimer disease (AD) dementia. METHODS:Participants (n = 33) had a diagnosis of MCI at baseline and a diagnosis of MCI or AD dementia at follow-up. Participants were categorized as "Stable-MCI" if they retained an MCI diagnosis at follow-up (mean follow-up = 18.0 months) or "Progressor-MCI" if they were diagnosed with AD dementia at follow-up (mean follow-up = 21.6 months). Awareness was measured using the residual from regressing a participant's objective memory score onto their subjective complaint score (i.e., residual<0 indicates overestimation of performance). Concern was assessed using a questionnaire examining the degree of concern when forgetting. Logistic regression was used to determine whether the presence of these syndromes could predict future diagnosis of AD dementia, and repeated measures analysis of covariance tests were used to examine longitudinal patterns of these syndromes. RESULTS: Baseline anosognosia was apparent in the Progressor-MCI group, whereas participants in the Stable-MCI group demonstrated relative awareness of their memory performance. Baseline awareness scores successfully predicted whether an individual would progress to AD-dementia. Neither group showed change in awareness of performance over time. Neither group showed differences in concern about memory performance at baseline or change in concern about performance over time. CONCLUSION: These data suggest that anosognosia may appear prior to the onset of AD dementia, while anosodiaphoria likely does not appear until later in the AD continuum. Additionally, neither group showed significant changes in awareness or concern over time, suggesting that change in these variables may happen over longer periods.
Authors: Robert S Wilson; Patricia A Boyle; Lei Yu; Lisa L Barnes; Joel Sytsma; Aron S Buchman; David A Bennett; Julie A Schneider Journal: Neurology Date: 2015-08-26 Impact factor: 9.910
Authors: E Kalbe; E Salmon; D Perani; V Holthoff; S Sorbi; A Elsner; S Weisenbach; M Brand; O Lenz; J Kessler; S Luedecke; P Ortelli; K Herholz Journal: Dement Geriatr Cogn Disord Date: 2005-03-30 Impact factor: 2.959
Authors: Frank Jessen; Rebecca E Amariglio; Martin van Boxtel; Monique Breteler; Mathieu Ceccaldi; Gaël Chételat; Bruno Dubois; Carole Dufouil; Kathryn A Ellis; Wiesje M van der Flier; Lidia Glodzik; Argonde C van Harten; Mony J de Leon; Pauline McHugh; Michelle M Mielke; Jose Luis Molinuevo; Lisa Mosconi; Ricardo S Osorio; Audrey Perrotin; Ronald C Petersen; Laura A Rabin; Lorena Rami; Barry Reisberg; Dorene M Rentz; Perminder S Sachdev; Vincent de la Sayette; Andrew J Saykin; Philip Scheltens; Melanie B Shulman; Melissa J Slavin; Reisa A Sperling; Robert Stewart; Olga Uspenskaya; Bruno Vellas; Pieter Jelle Visser; Michael Wagner Journal: Alzheimers Dement Date: 2014-05-03 Impact factor: 21.566
Authors: Federico d'Oleire Uquillas; Heidi I L Jacobs; Aaron P Schultz; Bernard J Hanseeuw; Rachel F Buckley; Jorge Sepulcre; Alvaro Pascual-Leone; Nancy J Donovan; Keith A Johnson; Reisa A Sperling; Patrizia Vannini Journal: Cereb Cortex Date: 2020-03-14 Impact factor: 5.357
Authors: Bernard J Hanseeuw; Matthew R Scott; Sietske A M Sikkes; Michael Properzi; Jennifer R Gatchel; Eric Salmon; Gad A Marshall; Patrizia Vannini Journal: Ann Neurol Date: 2019-12-05 Impact factor: 10.422
Authors: Floor M van Oudenhoven; Sophie H N Swinkels; Tobias Hartmann; Hilkka Soininen; Anneke M J van Hees; Dimitris Rizopoulos Journal: BMC Med Res Methodol Date: 2019-07-25 Impact factor: 4.615